# US 10,946,051 B2 · Strain of Bifidobacterium animalis subsp. lactis CECT 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,051 B2
- Document ID: US10946051B2
- Status: Granted
- Kind: B2
- Application number: 14/905,270
- Filed: 2014-07-17
- Published: 2016-05-26
- Granted: 2021-03-16
- Earliest claimed: 2013-07-18
- Assignees: Biopolis, S.L.
- Applicants: Biopolis, S.L.
- Inventors: Patricia Martorell Guerola; Mª Empar Chenoll Cuadros; Daniel Ramón Vidal; Pepa Ortiz Serrano; Silvia Llopis Pla; Núria Gonzalez Martínez; Salvador Genovés Martínez; Beatriz Casinos Ramo; Ángela Silva Angulo; Amaya Aleixandre
- Web page: https://patentgrep.com/patent/US10946051B2

## CPC

- A61K 35/745: Bifidobacteria
- A23C 9/1234: {characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.}
- A23C 11/106: {Addition of, or treatment with, microorganisms (A23C20/025 takes precedence)}
- A23L 2/02: containing fruit or vegetable juices
- A23L 2/382: {fermented (fermented nut meats or seeds A23L25/40; fermented milk preparations A23C9/12; addition of bacteria for nutritional purposes A23L33/135)}
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A23L 11/65: Soy drinks
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- C12N 1/205: Bacterial isolates
- A23V 2400/515: Animalis
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23C: DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF (preservation thereof A23B11/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The invention is applicable within the food and pharmaceutical industry. More specifically, it relates to a novel strain of the species Bifidobacterium animalis subsp. lactis CECT 8145, the cell components, metabolites and secreted molecules thereof, which, incorporated into food and/or pharmaceutical formulations, can be used in the treatment and/or prevention of excess weight and obesity and related diseases such as metabolic syndrome, hypertension, glycemia, inflammation, type 2 diabetes, cardiovascular diseases, hypercholesterolemia, hormonal alterations, infertility, etc.

## Claims

### Claim 1

A composition comprising:
a strain belonging to the species Bifidobacterium animalis subsp. Lactis of accession number CECT8145;
and a food formulation selected from the group consisting of fruit juice, vegetable juice, ice cream, infant formula, milk, yogurt, cheese, fermented milk, powder milk, cereals, bakery products, cereal-based products, nutritional supplements, soft drinks and dietary supplements.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the strain is in the form of viable cells.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the strain is in the form of nonviable cells.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the strain is present in an amount of between 105 CFU and 1012 CFU per gram or millilitre of the composition.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the composition is a pharmaceutical composition.

### Claim 6 (depends on 1)

The composition according to claim 1, comprising at least one other microorganism selected from the group consisting of Lactobacillus, Streptococcus, Bifidobacterium, Saccharomyces, Kluyveromyces, L. rhamnosus, L. delbrueckii subsp. bulgaricus, L. kefir, L. parakefir, L. brevis, L. casei, L. plantarum, L. fermentum, L. paracasei, L. acidophilus, L. paraplantarum, L. reuteri, S. thermophilus, B. longum, B. breve, B. bifidum, B. catenulatum, B. adolescentis, B. pseudocatenulatum, S. cerevisiae, S. boulardii, K. lactis, and K. marxianus.

### Claim 7 (depends on 1)

A method for the treatment of overweight, obesity, or related diseases comprising administering to a subject in need thereof a therapeutically effective amount of the composition according to claim 1.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the related diseases are selected from the group consisting of metabolic syndrome, hypertension, glycemia, inflammation, type-2 diabetes, cardiovascular disease, hypercholesterolemia, hormonal disorders and infertility.